Articles from FineHeart

FineHeart S.A., a clinical-stage medtech company developing breakthrough solutions for cardiology, announces the appointment of Sébastien Robitaille as Chief Financial Officer.

FineHeart S.A., a clinical-stage medtech company developing breakthrough solutions for cardiology, announces the extension of its ISO 13485:2016 certification to cover all processes related to the production of its fully implantable cardiac assist device, the FlowMaker®.

FineHeart, a clinical-stage MedTech company developing innovative medical devices for heart failure, has achieved a major milestone in its "First in Human" study, clinically confirming the proof of concept for FlowMaker®.

FineHeart S.A, a clinical-stage medtech company developing breakthrough solutions for cardiology, is pleased to announce the appointment of André-Jacques Auberton-Hervé to its Board of Directors.

FineHeart S.A., a clinical stage medical device company developing innovative devices for cardiology today announced the successful filing of six new international patents for its FlowMaker®, a fully implantable device for the treatment of patients with advanced heart failure.

FineHeart S.A, a medical device company developing the FLOWMAKER®, a fully implantable cardiac output restoration system (ICOMS) to address the unmet needs of patients suffering from severe heart failure, announced today that its first two patents have been granted in China by the CNIPA - China National Intellectual Property Administration -.

FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced that it had been awarded a €2.5 million grant by the European Commission (EC) under the highly selective EIC Accelerator program. This grant has the potential to be followed by an equity investment of up to €15 million by the EIC Fund at the company’s next series C funding round. It will support the industrialization and clinical trials of the ICOMS FLOWMAKER®.

FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification. This certifies the compliance of FineHeart's quality management system with medical device industry regulations and has been issued following an audit by BSI, the independent, internationally recognized, accreditation organization.

FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced further funding of €6 million bringing the Series B total to €21 million, giving FineHeart a cash runway until the end of 2023. This financing comes in addition to the €15 million raised in June 2021 with the pool of industrial and independent investors: Lauak Group, Doliam, FineHeart Founders' Holding which brought together international private investors, mainly from the cardiology sector and the European investment fund Verve Ventures. They joined historical shareholders Irdi, Aquiti, Galia, Broadview Ventures, and M Capital.